Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month.
The Israel-based company said that Ajovy is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide ligand and blocks its binding to the receptor.
Read the whole story on our sister site, Drug Delivery Business News
The post Teva wins EU nod for Ajovy migraine prophylactic appeared first on MassDevice.